Management

ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

• Founder of Vonderscher&Co GmbH
• Senior executive with a broad R&D experience in the pharmaceutical industry
• Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
• Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
• Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
• Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
• Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
• Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
• Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)

Dr Pietro Scalfaro, MD, MBA, SVP Head of Clinical Development Chief Medical Officer

• In charge of strategy and operational management of the clinical drug programs
• Wide range experience in various roles in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases
• Set up a Personalised Medicine Business Unit at Debiopharm Group and involved during start-up of eHealth and diagnostic companies (Biocartis, Sophia Genetics, Agendia, Immunexpress, Pryv, Orphanalytics)
• Practicing physician, with degrees from the University of Lausanne and the Swiss Medical Association in Paediatrics, Intensive Care and MBA

Dr Raphaël Darteil, PhD, SVP Head of non-clinical Development & Profiling

• Responsible for non-clinical development and in vitro / in vivo compound profiling
• More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
• Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
• COO and Member of the board at Genfit
• Various positions in the department of Gene Therapy of Aventis both in France and in the US
• Co-inventor of the patent protecting the use of Elafibranor (Phase III) for the treatment of NASH patients
• He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I

Keltoum Medji, MBA, VP Finance and Strategic Development

• Responsible for all finance activities including fundraising, investors relations, strategic partnerships
• More than 20 years’ experience in Orthopedic business supporting growth by an increased collaboration with supply chain & commercial organizations
• Strong experience in change management through diverse organizational changes as M&A, restructuring, reorganizations
• Graduated with a Master’s degree in Economics & Business Management and an MBA from EM Lyon Business School

Claudi Miquel, VP Legal Affairs & Board Secretary

• Responsible for all legal affairs and Secretary of the Board of Directors
• 15 years’ experience as an attorney as well as lead counsel for international organizations across different jurisdictions
• Experience in transactional, financing, IP, and corporate/governance matters
• Graduated with a master’s degree in business law from Vanderbilt University law school

Pete Leone, MBA, Head of Business Development & Licensing

• Responsible for Business development
• More than 30 years of C-level experience at public and private biopharmaceutical companies, with over $6 billion in upfront payments and potential milestones from business development transactions that he led to closure
• Various management roles at Arrowhead Pharmaceuticals (Nasdaq: ARWR), including business development, was CBO at Bicycle Therapeutics (Nasdaq: BCYC), and previously, a cofounder of three venture-backed companies, including Mersana Therapeutics (Nasdaq: MRSN)
• Corporate and not-for-profit board member, including SeromYx Systems, Third Monday Foundation, and Nuestros Pequeños Hermanos – NPH USA Northeast region
• Holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business

History of ENYO Pharma with virus biomimetism

Our story began in 2014 when experts in virus-host protein interactions from the French Infectiology Research Center (Inserm) in Lyon, France and pharmaceutical industry executives specialized in drug development developed a unique drug discovery platform based on biomimetism inspired by viruses.

Founders

Jacky Vonderscher, PhD, CEO: see above

Laurène Meyniel-Schicklin, Engineer: Head of Bioinformatics, 15 years experience in omics data management and analysis for drug discovery Team and project leader, responsible for bioinformatics, scientific data management and analysis ; Engineer in Biology and Computer Science (Genopole, Evry)

Benoît de Chassey, PhD: Head of Drug Discovery Platform, 18 years experience in high-throughput approaches in drug discovery ; Former project leader in functional screenings at Aptanomics

Patrice André, MD, PhD: Medical Advisor, Professor Emeritus of Virology at Charles Mérieux Lyon Sud Medical School, Lyon 1 University; Former Head of clinical virology department at the Hospices Civils de Lyon; Former Team leader at the International Center for Infectiology Research, Inserm, CNRS, ENS Lyon

Vincent Lotteau, PhD: Advisor, Inserm Research Director, Immunologist ; Team leader at the International Center for Infectiology Research; Former director of Inserm Unit « Fundamental and clinical immunology »; Participated to several French governmental missions

Jean-Jacques Garaud, MD: Co-founder and CEO of Inotrem SA (2013-2021); Executive vice-president Medical and Scientific Affairs, Inotrem SA; A senior executive with a broad R&D experience in the pharmaceutical industry; Executive VP Head of Pharma Research and Early Development at Roche; Executive VP Head of Development and CMO at Roche ; Previously held other senior positions with Shering-Plough in the USA and with Novartis in the USA and Switzerland

Inserm Transfert Initiative: Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012; It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies’ development.